All In Biotech

Drug Trial Radar · NCT06700148

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds

A Randomized, Blinded, Peer-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7-17 Year Olds

Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 840 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

840

Actual

Start

Dec 14, 2024

Primary completion

Feb 19, 2025

Study completion Jul 16, 2025

Sponsor

Lead sponsor
CanSino Biologics Inc.Industry
Sponsor type
Industry
First posted
Nov 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 7 years, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, blinded, peer-controlled study. There will be 2 treatment groups, screened subjects were given study numbers in the order of enrollment and randomly assigned to the test and control groups in a 1:1 ratio. Subjects were required to complete a 1-dose immunization program with 0.5 ml of vaccine in both the test and control groups, afterwards some subjects entered the immune persistence group.

Conditions

  • Meningococcal Meningitis

Interventions

  • MCV4Biological

    1 dose of MCV4 on Day 0

  • MPSV4Biological

    1 dose of MPSV4 on Day0

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Meningococcal Antibody Positive Conversion Rates and GMT for Groups A, C, Y, and W135 in All SubjectsTime frame: 30 Days After Immunization
  2. Geometric Mean Titer (GMT) for Groups A, C, Y, and W135 in All SubjectsTime frame: 30 Days after immunization
  3. Incidence of adverse reactions in all subjectsTime frame: Within 30 mins after immunization
  4. Incidence of adverse reactions/events in all subjectsTime frame: Within 7 days after immunization
  5. Incidence of adverse reactions/events in all subjectsTime frame: Within 30 days after immunization

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Dengfeng Center for Disease Control and Prevention

    Dengfeng, China

  • Kaifeng Center for Disease Control and Prevention

    Kaifeng, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.